Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?
09.06.2026 08:08
In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials, and they plan global regulatory filings based on these data. At the same time, Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant...
The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains
09.06.2026 07:44
The Hashgraph Group (THG) today announced a strategic collaboration with science and technology company Merck, that extends its TrackTraceDigital Product Passport (DPP) platform. Built on Hedera and designed to support compliance requirements for the global supply chain industry, the collaboration aims to meet the EU's incoming product transparency regulations, ensuring product trust, quality, and improved sustainability. This integration of digital and physical authentication technologies is an
Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector
08.06.2026 12:00
Merck Appoints New Heads of Discovery Solutions and Strategy & BD for Life Science Clara Sattler de Sousa e Brito appointed Head of Discovery Solutions, bringing extensive international leadership experience across healthcare, medtech and the chemical industry. Robert Machinek appointed Head of Strategy & Business Development, bringing deep expertise in life science strategy, M&A and digital transformation Darmstadt, Germany, June 08, 2026 (GLOBE NEWSWIRE) -- Clara Sattler de Sousa e Brito appoi
Discover RadNet And 2 Other Stocks Estimated To Be Trading Below Intrinsic Value
08.06.2026 11:38
Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases
07.06.2026 12:08
In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence, metastasis, and death compared with Keytruda alone. At the same time, Moderna secured up to US$50.00 million in funding from CEPI for its Bundibugyo ebolavirus mRNA vaccine candidate, underscoring how its platform is being applied to both oncology and emerging infectious...
Assessing Merck (MRK) Valuation After Recent Share Price Momentum And Earnings Growth
06.06.2026 02:13
Merck stock snapshot after recent performance Merck (MRK) has drawn investor attention after a period of steady share price movement, with the stock closing at US$120.79 and recording positive returns over the past week, month and past 3 months. At the same time, Merck reports annual revenue of US$65.8b and net income of US$8.9b, with both metrics showing annual growth. These figures help frame how recent price action lines up with the company’s current scale and profitability. See our latest...
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
05.06.2026 15:55
Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 […]
Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
05.06.2026 14:17
Merck (NYSE:MRK) has agreed to a settlement worth more than $50m to resolve over 200 lawsuits related to its Gardasil HPV vaccine. The settlement concludes a significant block of litigation while Merck continues to state that Gardasil is safe and effective. This development comes as Merck's share price stands at $120.26 and the stock has returned 60.6% over the past year. For investors watching Merck, the Gardasil settlement is a material legal event that helps clear a long running source...
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
05.06.2026 13:35
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
05.06.2026 13:30
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
05.06.2026 12:25
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent expiry in 2028. For more on MRK stock.
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
05.06.2026 03:46
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.
Why Is Moderna (MRNA) Stock Rocketing Higher Today
05.06.2026 02:45
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as the company, along with partner Merck, presented positive long-term data for its personalized mRNA-based cancer vaccine.
BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value
04.06.2026 11:38
The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
03.06.2026 07:05
It is finally bouncing back after several challenging years.
Merck & Co. (MRK) Announces Quarterly Dividend
02.06.2026 14:13
Merck & Co., Inc. (NYSE:MRK) is one of the best inexpensive stocks to invest in right now. Merck & Co., Inc. (NYSE:MRK) announced on May 26 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q3 2026, with payments set to be made on July […]
3 Stocks Estimated To Be Trading Up To 49.6% Below Their Intrinsic Value
02.06.2026 11:38
Over the last 7 days, the United States market has risen 1.6%, contributing to a 28% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and value appreciation.
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
02.06.2026 10:45
RAHWAY, N.J., June 02, 2026--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth
02.06.2026 09:38
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification Transcript
02.06.2026 09:12
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification June 1, 2026 7:00 PM...